Author:
Ganesan Nirmala,Sharma Akshata
Reference37 articles.
1. Shabir S, Gill PK (2020) Global scenario on ovarian cancer – its dynamics, relative survival, treatment, and epidemiology. Adesh Univ J Med Sci Res 2(1):17–25
2. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H (2019) Ovarian cancer in the world: epidemiology and risk factors. Int J Women’s Health 11:287–299. https://doi.org/10.2147/IJWH.S197604
3. Modugno F, Edwards RP (2012) Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. Int J Gynecol Cancer 22(8):S45–S57. https://doi.org/10.1097/IGC.0b013e31826bd1f2
4. Sonego M, Baldassarre G (2020) A new role for IDH1 in the control of ovarian cancer cells metabolism and senescence. Ann Transl Med 8(12):780. https://doi.org/10.21037/atm.2020.02.62
5. Li S, Xinglong Z, Lei Z, Miaomiao W, Zhifa Z, Ping L (2020) Mutation of isocitrate dehydrogenase 1 in cholangiocarcinoma impairs tumor progression by inhibiting isocitrate metabolism. Front Endocrinol 11:1664–2392